What were the key drivers of Intuitive Surgical's revenue growth in 2017?

Revenue growth was primarily driven by an increase in the number of da Vinci procedures performed worldwide (up 16%), leading to higher instrument and accessory revenue (up 17%). Systems revenue also contributed significantly, increasing by 15% due to a 27% increase in system shipments.

What is the significance of the da Vinci X Surgical System launch?

The launch of the da Vinci X Surgical System in May 2017 is significant because it offers advanced robotic-assisted surgery capabilities at a lower price point, making the technology more accessible to a wider range of hospitals and potentially driving further market penetration and adoption.

How is Intuitive Surgical managing its installed base and recurring revenue streams?

Intuitive Surgical benefits from a growing installed base of da Vinci Surgical Systems (up 13% to 4,409 units). Recurring revenue, consisting of instrument, accessory, and service revenue, now accounts for 72% of total revenue, indicating a stable and growing revenue stream beyond initial system sales.

What is the company's financial health and how is it returning value to shareholders?

The company maintains a strong financial position with $3.8 billion in cash, cash equivalents, and investments as of December 31, 2017. In 2017, Intuitive Surgical executed an accelerated share repurchase program totaling $2.3 billion, demonstrating a commitment to returning capital to shareholders while continuing to invest in R&D and market expansion.

ISRG 10-K FY2017 Annual Report — Revenue, Net Income, EPS

Summary

Intuitive Surgical Inc. (ISRG) reported strong performance for the fiscal year ending December 31, 2017, with total revenue increasing by 16% to $3.1 billion, driven by a 16% increase in da Vinci procedures performed worldwide. The company saw significant growth in instrument and accessory revenue (up 17%) and systems revenue (up 15%). The installed base of da Vinci Surgical Systems grew by 13% to 4,409 units globally. The company also launched the da Vinci X Surgical System in May 2017, offering advanced robotic-assisted surgery capabilities at a lower cost, and received FDA clearance for it shortly after. Financially, ISRG demonstrated robust operational efficiency with a gross profit margin of 70.1%. The company's strategy of focusing on value for patients, surgeons, and hospitals continues to drive adoption across multiple surgical specialties, with general surgery and urology showing particularly strong growth. While the company repurchased a substantial amount of its stock in 2017, it maintained a strong liquidity position with $3.8 billion in cash, cash equivalents, and investments.

Key Highlights

1Total revenue grew 16% year-over-year to $3.1 billion in 2017.
2Worldwide da Vinci procedures increased by 16% to approximately 877,000 in 2017.
3Instrument and accessory revenue increased by 17% to $1.6 billion.
4Systems revenue increased by 15% to $910.2 million, with 684 systems shipped.
5The installed base of da Vinci Surgical Systems expanded by 13% to 4,409 units globally.
6The company launched the da Vinci X Surgical System, broadening market access.
7Gross profit margin remained strong at 70.1%.

Revenue	$3.14B
Cost of Revenue	$934.80M
Gross Profit	$2.20B
R&D Expenses	$328.60M
SG&A Expenses	$810.50M
Operating Expenses	$1.14B
Operating Income	$1.06B
Net Income	$670.90M
EPS (Basic)	$2.00
EPS (Diluted)	$1.92
Shares Outstanding (Basic)	335.10M
Shares Outstanding (Diluted)	348.90M

INTUITIVE SURGICAL INC Annual Report, Year Ended Dec 31, 2017

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions